Kybernin

Antithrombin III, the active ingredient in Kybernin, is an anticoagulant presented as an injectable solution for intravenous use. It is indicated for the prevention and treatment of thromboembolic events in patients with antithrombin deficiency and for managing heparin resistance.

GNH USA supplies Kybernin as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.

Kybernin is used in the anticoagulation pathway to address deficiencies and resistance related to antithrombin activity.

- Antithrombin deficiency: restores antithrombin levels to prevent clot formation. - Heparin resistance: enhances heparin efficacy by providing the necessary cofactor. - Cardiopulmonary bypass surgery: supports anticoagulation when endogenous antithrombin is insufficient.

Kybernin may be associated with a range of adverse reactions following intravenous administration.

Common Side Effects: - Infusion‑related fever or chills. - Mild hypotension during or shortly after infusion. - Localized erythema or swelling at the injection site. - Transient headache.

Serious or Rare Side Effects: - Severe allergic reaction or anaphylaxis. - Significant bleeding or hemorrhage. - Thrombotic events despite therapy. - Acute renal impairment. - Development of antibodies against antithrombin.

Before using Kybernin, clinicians should consider several safety measures.

- Monitor antithrombin activity: check plasma levels before and during therapy. - Assess bleeding risk: evaluate patient history of hemorrhage. - Caution in thrombosis history: avoid if recent thrombotic events occurred. - Concomitant anticoagulants: adjust doses of other agents to prevent over‑anticoagulation. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Kybernin can interact with other anticoagulant and antithrombotic agents.

Major Interactions (Avoid): - Concurrent high‑dose heparin: may cause excessive anticoagulation. - Direct thrombin inhibitors (e.g., dabigatran): increased risk of bleeding.

Moderate Interactions (Monitor Closely): - Warfarin: may require INR monitoring and dose adjustment. - Low molecular weight heparins: monitor anti‑Xa activity. - Antiplatelet agents (e.g., aspirin, clopidogrel): heightened bleeding tendency.